The Ahmanson-UCLA Cardiomyopathy Center is conducting a clinical research study that will assess the use of the medication metformin to improve quality of life, exercise capacity, and improved outcomes in heart failure patients with pre-DM or early DM (type II).
If the patient participates in this study, the patient will receive the drug metformin for approximately 3 months. During the study the patient will undergo comprehensive testing which includes blood draws and echocardiograms. The patient will also fill out a questionnaire. The patient must be 18 years old to participate.
symptomatic HF of any etiology age ≥ 18 years fasting blood sugar equal or greater than 100 mg/dL, or pre-DM (HbA1c 5.7 - 6.4%) or early DM (HbA1c ≥ 6.5%)
Exclusion Criteria:
current metformin therapy or other anti-diabetic therapy previous intolerance to metformin therapy renal dysfunction (Cr >1.5 in men or > 1.4 in women or creatinine clearance < 60 ml/minute) history of lactic acidosis current or planned pregnancy or breast-feeding
